Atypical pharmacokinetics affect symptomatic activity in Alzheimer's patients, suggesting trial design implications.
The exposure increase at 12 months and the dual pharmacology of HMT explain the unexpected symptomatic activity of low dose MTC. The data suggest it is not possible to maintain comparable urinary discolouration without therapeutic activity in a standard placebo-controlled trial design.
No takes yet. Share an insight, caveat, or question.
Maanen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: